941 resultados para systemic vascular resistance


Relevância:

100.00% 100.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

The hemodynamic effects of total intravenous anesthesia with propofol or propofol in combination with lidocaine were investigated in 12 dogs. In the P group (n=6), the dogs received a loading dose (LD) of 6mg kg-1 of propofol followed by a constant rate infusion (CRI) of 1.25mg kg-1 min-1. In the PL group (n=6), dogs received a LD of 6mg kg-1 of propofol and 1.5mg kg-1 of lidocaine followed by CRIs of 1.0mg kg-1 min-1 and 0.25mg kg-1 min-1 of propofol and lidocaine, respectively. The animals were instrumented for measurement of hemodynamic variables and bispectral index (BIS), recorded at 75, 90, 105 and 120 minutes during anesthesia. Cardiac index, stroke index, systolic, diastolic and mean arterial blood pressures were lower in the P group compared to the PL group (P<0.05). There were no significant differences between groups in heart rate, systemic vascular resistance index and BIS. Plasma concentrations of propofol were lower in group PL than in group P (medians of 5.7 to 6.1mg mL-1 in the P group versus 3.1 to 3.7mg mL-1 in the PL group). Measured lidocaine plasma concentrations (medians of 2.27 to 2.51mg mL-1) were in the range that result in analgesia and were below values that result in toxicity in dogs. The BIS values observed in the two groups of dogs were compatible with deep anesthesia (mean values of 43-46 and 45-49 in groups P and PL, respectively). Maintenance of deep anesthesia with lidocaine-propofol causes less cardiovascular depression than equipotent doses of propofol alone.

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Septic shock remains one of the most common challenges for the small animal practicing, presenting high mortality rates frequently associated with late identification of this syndrome, as well as an inappropriate treatment. In general, disruption of homeostasis occurs with an intense activation of inflammatory cascade, which leads to a damage to endothelial cells and an exposure to these cytokines, which will result in vasodilation and increased capillary permeability. Thus, there is a drop in blood pressure, even after aggressive fluid resuscitation. Therefore, drugs such as vasopressors, which act by increasing systemic vascular resistance, and inotropes, which have an effect on heart pump, should be administered in order to raise blood pressure, ensuring adequate tissue perfusion. The objective of this review was to gather information about the various drugs used in vasopressors/inotropes therapy, trying to explain the role of each one in different situations, in order to increase the survival rate in dogs affected with septic shock

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Relevância:

100.00% 100.00%

Publicador:

Resumo:

Aim: The renin-angiotensin-aldosterone system (RAAS) has dual pathways to angiotensin II production; therefore, multiple blockages may be useful in heart failure. In this study, we evaluated the short-term haemodynamic effects of aliskiren, a direct renin inhibitor, in patients with decompensated severe heart failure who were also taking angiotensin-converting enzyme ( ACE) inhibitors. Materials and methods: A total of 16 patients (14 men, two women, mean age: 60.3 years) were enrolled in the study. The inclusion criteria included hospitalisation due to decompensated heart failure, ACE inhibitor use, and an ejection fraction < 40% (mean: 21.9 +/- 6.7%). The exclusion criteria were: creatinine > 2.0 mg/dl, cardiac pacemaker, serum K+ > 5.5 mEq/l, and systolic blood pressure < 70 mmHg. Patients either received 150 mg/d aliskiren for 7 days (aliskiren group, n = 10) or did not receive aliskiren (control group, n = 6). Primary end points were systemic vascular resistance and cardiac index values. Repeated-measures analysis of variance (ANOVA) was used to assess variables before and after intervention. A two-sided p-value < 0.05 was considered statistically significant. Results: Compared to pre-intervention levels, systemic vascular resistance was reduced by 20.4% in aliskiren patients, but it increased by 2.9% in control patients (p = 0.038). The cardiac index was not significantly increased by 19.0% in aliskiren patients, but decreased by 8.4% in control patients (p = 0.127). No differences in the pulmonary capillary or systolic blood pressure values were observed between the groups. Conclusion: Aliskiren use reduced systemic vascular resistance in patients with decompensated heart failure taking ACE inhibitors.